European Commission Approves New Drug Combination for First-Line Treatment of Aggressive Lung Cancer
The European Commission has approved the combination of Zepzelca (lurbinectedin) with the immunotherapy atezolizumab as first-line maintenance therapy for extensive-stage small cell lung cancer. The approval is based on results from the IMforte study, which showed a 46% reduction in the risk of disease progression or death compared with atezolizumab monotherapy.
The Death of Carboplatin and the Era of the 'Chemo-Immuno' Tandem: Why the Approval of Zepzelca in Europe Changes the Oncology Landscape
[The Core]: What's Really Happening
At first glance, it seems like a routine event on May 31, 2026—the European Commission approved yet another combination for treating extensive-stage small cell lung cancer. But if you look deeper at the numbers, you'll see a tectonic shift. For the first time in 30 years, we have not just 'another option' but a real alternative to platinum-based therapy. The combination of Zepzelca (lurbinectedin) with atezolizumab showed a 46% reduction in the risk of progression or death compared with immunotherapy alone. This is not an incremental improvement. It's a quantum leap.
The essence is that small cell lung cancer is the type of oncology where, for the last 20 years, all attempts to improve the standard chemotherapy have been shattered by resistance and toxicity. Platinum (carboplatin or cisplatin) in combination with etoposide has been and remains the 'gold standard' for induction therapy. But what to do next, after those 4-6 cycles are over? Until today, the only options for maintenance therapy were simply 'watch and wait' or atezolizumab monotherapy, which provided a survival benefit but didn't fully address the issue.
Now we have lurbinectedin—an alkylating agent that binds to the minor groove of DNA and causes double-strand breaks. And it works synergistically with atezolizumab. Why? Because chemotherapy, by killing cancer cells, releases neoantigens that 'highlight' the tumor for the immune system. Immunotherapy removes the brakes from T-cells. Together, they create a positive feedback loop. And the IMforte study proved this not only in progression-free survival (primary endpoint) but also in overall survival—a 27% reduction in the risk of death. That's the number insurance companies pay for.
Timeline and Context
I want to draw your attention to the dates because they reveal the real story. On March 27, 2026, the European Medicines Agency (EMA) issued a positive opinion from the CHMP committee. That was a signal that approval was inevitable. But the European Commission dragged its feet for exactly two months and five days, issuing the final decision on May 31. During those two months, two important things happened.
First: in April 2026, Jazz Pharmaceuticals reported record sales of Zepzelca—$101 million in the first quarter alone, up 60% from the previous year. Meanwhile, Jazz's total revenue for 2025 was $4.3 billion, with a forecast for 2026 of $4.25-4.5 billion. Zepzelca brought in $307 million in 2025. The numbers indicate that the drug has already become a 'franchise' for the company. And the European approval adds at least another 20-25% of the market to that franchise.
Second: the FDA approved the same combination back in late 2025. The United States was first. It was followed by Switzerland, the UAE, Oman, Israel, Taiwan, and several Latin American countries (Uruguay, Peru, Paraguay, Ecuador). Europe is the thirteenth jurisdiction. And this is important because usually the European regulator either precedes the FDA or moves in parallel. Here we see a delay of about six months. Why? Because the EMA requested additional safety data—especially regarding hepatotoxicity. Lurbinectedin is metabolized in the liver via CYP3A4, and 8% of patients in the phase 3 trial experienced grade 3 transaminase elevation. The Europeans wanted to ensure this wouldn't become a problem in real-world clinical practice.
Now, with EMA approval and orphan drug designation (small cell lung cancer affects fewer than 5 in 10,000 people in the EU), Zepzelca gets 10 years of market exclusivity in Europe. This is a huge asset for PharmaMar and Jazz Pharmaceuticals.
Who Wins and Who Loses
Let's start with the obvious winners. Jazz Pharmaceuticals (NASDAQ: JAZZ). Their stock is currently trading around $240, with a market cap of $15 billion. The stock has risen 41% over the past year. And this is not the peak yet. Wall Street analysts (Barclays, Goldman) have already raised target prices to $253-270. Why? Because European approval opens access to a market of 62,000 new cases per year. Even if only 40% of them receive this therapy (and the indication is maintenance therapy after induction, which applies to about 70-80% of patients), that's 25,000-30,000 patients per year. With a course price in Europe of around €25,000-30,000 (in the US, Zepzelca costs about $28,000 per cycle, and maintenance therapy is up to 6 cycles), the potential from Europe alone is €750 million annually.
The second winner is Roche with their atezolizumab (Tecentriq). Roche sponsored the IMforte study and provided its drug free of charge. This is standard practice, but Roche now gets an expanded indication for Tecentriq in combination, allowing them to compete with Merck (Keytruda) and BMS (Opdivo) in the SCLC segment. Tecentriq has been approved in first-line SCLC since 2019, but now with the partner Zepzelca in maintenance, Roche can offer a 'complete package'—induction with carboplatin/etoposide + Tecentriq, followed by maintenance with Tecentriq + Zepzelca. This is vertical integration of treatment.
The third winner is PharmaMar. The Spanish biotech company that discovered lurbinectedin. They receive royalties from Jazz (reportedly around 15-20% of net sales). With projected global sales of Zepzelca reaching $800 million by 2028, PharmaMar will receive $120-160 million annually with virtually no costs. This transforms them from a loss-making research center into a cash cow.
Who loses? Merck & Co. with their Keytruda. Keytruda has not shown benefit in first-line SCLC (the KEYNOTE-604 study did not achieve statistically significant improvement in overall survival). Now that Jazz/Roche are taking over maintenance therapy, Merck simply has no arguments in this subtype of lung cancer. The second loser is Bristol-Myers Squibb with Opdivo. They have the Opdivo + Yervoy combination, but the toxicity of this regimen in SCLC proved to outweigh the benefit. The third loser is hospital pharmacies that purchased generic carboplatin and etoposide. Margins on generics are 70-80%, but now doctors will switch to the branded combination Zepzelca + Tecentriq, where the margin for the hospital is lower, but patients live longer—and hospitals earn more through bundled episode payments.
What the Media Isn't Saying
Here's the real insight that isn't in press releases and news articles.
First: the mechanism of lurbinectedin is not fully understood. Officially, it is claimed as an RNA polymerase II inhibitor causing transcription degradation. But recent preprints (not yet published but circulating among ASCO experts) show that lurbinectedin also modulates PD-L1 expression on the surface of cancer cells. It doesn't just kill the cell—it 'redresses' surviving cells, making them more vulnerable to atezolizumab. If this is confirmed in post-marketing studies, we are dealing not just with a combination but with 'immunogenic chemotherapy'—a new class of drugs. And Jazz knows this but isn't disclosing it because the patent on the mechanism of action could be extended by another 5-7 years.
Second, what's hidden: toxicity. In the IMforte study, the rate of grade 3 and 4 neutropenia was 44% in the combination group versus 16% in the atezolizumab group. Febrile neutropenia occurred in 18% of patients. This means that every fifth patient needs to be hospitalized with fever and risk of sepsis. In real-world clinical practice, outside the ideal conditions of a clinical trial, this percentage will be higher—around 25-30%. European oncologists are already discussing whether prophylactic G-CSF (filgrastim) is needed for all patients on the combination. But G-CSF costs about €3,000 per course, adding an additional burden to healthcare budgets.
Third, what's being kept quiet: the price. Jazz Pharmaceuticals has not yet announced the price for Europe. But in the US, the combination costs about $35,000 per cycle ($28,000 for Zepzelca, $7,000 for Tecentriq). With 6 cycles of maintenance, that's $210,000 per patient. In Europe, due to reference pricing, the price will be lower—around €150,000 for a full course. But even that is 10 times more expensive than carboplatin/etoposide (about €15,000 for induction). The question is whether European healthcare systems are willing to pay such a price for an additional 2-3 months of life. In the UK, NICE has already started the appraisal process, and analysts predict that NICE will demand a 40-50% discount from the stated price, otherwise the combination will not pass the cost-effectiveness threshold of £30,000 per QALY.
Forecast: Next 30 Days and 90 Days
Next 30 days. National health institutes of European countries (Germany—G-BA, France—HAS, Italy—AIFA) will begin price negotiations. The key battle will unfold in Germany, where a system of free pricing applies in the first 12 months after approval. Jazz must set a price by July 1, 2026, otherwise a reference group will take effect from August 1. My forecast: they will set a price around €18,000 per cycle (25% lower than in the US), but with discounts for large hospital networks. Within 30 days, we will see the first treatment recommendations from ESMO (European Society for Medical Oncology)—most likely, the combination will receive a level IA recommendation (highest score) for maintenance therapy.
Also in the next 30 days, Jazz will announce the start of negotiations with NHS England. Given that in the UK, 7,500 cases of SCLC are diagnosed annually, and about 5,000 of them are extensive stage, the potential market for Jazz is £500-700 million. But NICE will demand outcome-based pricing, where Jazz receives full payment only for patients who live more than 12 months without progression. Such schemes already work for CAR-T and some immunotherapies, but for chemotherapy—it's a first.
Next 90 days. By September 2026, we will see the first real-world clinical data from Europe. Patient registries will be launched (at least in Germany, France, and Spain). Oncologists will start reporting cases of hepatotoxicity—this will be a key factor limiting use. If the rate of serious (grade 3-4) transaminase elevations exceeds 15% in real-world practice, the combination will be used only in large oncology centers, not in district hospitals.
Also within 90 days, Jazz Pharmaceuticals will file for an expanded indication—now for second-line therapy. Data from the ATLANTIS-2 study (second line after platinum) are expected by October 2026. If these data are positive (and preliminary phase 2 results suggest they are), the market for Zepzelca will grow by another 30-40%. In this scenario, the target price for Jazz shares could reach $280-300 by the end of 2026.
And finally, what I'm watching: an acquisition. Jazz is a company with a $15 billion market cap, making it a 'tasty morsel' for Big Pharma. Pfizer, which is currently looking for assets to strengthen its oncology portfolio after the decline in Paxlovid sales, is considering Jazz as a potential target. Roche may also be interested—they already have Tecentriq, and acquiring Jazz would give them full control over the combination. The price of such an acquisition would be $25-28 billion (a 60-80% premium over the current price). The timeline—the next 12-18 months. But initial informal contacts may have already begun, following the European approval.
This is not just the approval of another drug. It's a paradigm shift in the treatment of one of the most aggressive cancers. And those who understand this have already been long on Jazz shares.
— Editorial Team
